keytruda
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda
MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
NICE knocks back MSD’s Keytruda for lung cancer indication
February 28, 2017Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda
MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …
MSD aims to get the jump on BMS treating bladder cancer
February 6, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
BMS receives $625 million patent settlement boost from Merck
January 23, 2017Sales and Marketing BMS, MSD, Merck, keytruda, opdivo
Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …
MSD and Lilly announce immuno-oncology collaboration
January 11, 2017Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly
MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …
MSD looks to jump the gun with combination immunotherapy application
January 11, 2017Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda
MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …
NICE approves MSD’s Keytruda for new cancer indication
December 1, 2016Medical Communications, Sales and Marketing MSD, NICE, keytruda
The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
